Geron GERN

NASDAQ GERN

$1.38 -0.02 (-1.78%)

As of: Sep 10, 2026 · 3:59 PM EDT

Key Stats

Market Cap914.60 Mn

P/E-13.59

P/S3.75

Div. Yield0.00

Total Debt (Qtr)120.13 Mn

Revenue Growth (1y) (Qtr)17.22

Add ratio to table…

About

Geron Corporation is a commercial stage biopharmaceutical company focused on changing the course of blood cancer. Its lead product RYTELO (imetelstat) is a first in class telomerase inhibitor that received FDA approval in June 2024 for adult patients with low to intermediate 1 risk myelodysplastic syndromes who have transfusion dependent anemia and have not responded to or are ineligible for erythropoiesis stimulating agents. The company also obtained European Commission approval in March 2025 for the same indication. Geron Corporation is advancing additional clinical programs to evaluate imetelstat in relapsed refractory myelofibrosis and other myeloid malignancies. The mechanism of action involves direct inhibition of the telomerase enzyme, which is overactive in malignant stem and progenitor cells, thereby limiting their proliferative capacity. Clinical data from the IMerge trial showed durable red blood cell transfusion independence and supported the drug’s potential disease modifying activity. These attributes position RYTELO as a novel therapeutic option in hematologic oncology.

The company generates revenue primarily from the sale of RYTELO in the United States following its commercial launch in June 2024. Sales are made to healthcare providers, hospitals and specialty clinics that administer the product to eligible patients. Additional revenue arises from limited access programs outside the United States through Named Patient Partnerships, which to date have contributed minimal amounts. Geron Corporation is preparing for a planned commercial launch in select European markets in 2026, which is expected to create a new revenue stream pending reimbursement and market access approvals. The company also pursues potential milestone payments and royalties from future collaborations, although no material license agreements are currently in place.

Geron Corporation holds a differentiated position in the hematologic oncology market as the sole approved telomerase inhibitor for myelodysplastic syndromes and is pursuing broader applications in myelofibrosis. Key competitors in lower risk MDS include erythropoiesis stimulating agents such as epoetin alfa and darbepoetin alfa, the agent luspatercept, and hypomethylating agents like azacitabine and decitabine. In relapsed refractory myelofibrosis the company faces competition from JAK inhibitors including ruxolitinib, fedratinib and momelotinib. Competitive advantages stem from its novel mechanism of action, clinical evidence of durable transfusion independence, potential disease modifying activity, strong payer access, orphan drug exclusivity and a growing patent portfolio extending into the 2030s. The drug has been incorporated into the National Comprehensive Cancer Network Guidelines as a preferred option in certain patient subgroups, reinforcing its clinical credibility. Furthermore, the orphan drug designation provides seven years of market exclusivity in the United States and ten years in the European Economic Area, limiting generic competition for a substantial period.

The company serves adult patients with low to intermediate 1 risk myelodysplastic syndromes who require red blood cell transfusions and are ineligible for erythropoiesis stimulating agents, as well as patients with relapsed refractory myelofibrosis who have progressed after JAK inhibitor therapy. These patient populations represent a significant unmet medical need, with estimates of tens of thousands of individuals in the United States alone. Customers also include hospitals, oncology clinics and specialized transfusion centers that administer the product and manage patient care. In addition, Geron Corporation works with health insurance providers, managed care organizations and government payers to secure coverage and reimbursement for RYTELO. The company’s patient support program, REACH4RYTELO, assists eligible individuals with access, affordability and education related to therapy.

Investment Thesis

▲ Bull case

Geron Corporation's RYTELO is positioned to capture significant unmet need in the lower-risk MDS second-line market, with management estimating approximately 8,000 eligible patients in the U.S. and a clear clinical pathway supported by updated NCCN guidelines recommending imetelstat as the preferred second-line treatment. The company's commercial strategy is executing effectively, with first and second-line patient starts increasing to 33% on a rolling 12-month basis in Q1 FY26, up from 30% in the prior quarter, reflecting successful targeted engagement with high-volume community accounts and the 3D surround sound marketing approach. This progression directly addresses a core commercial lever—shifting utilization earlier in the treatment journey—where real-world evidence from the IMerge study and recent Blood Cancer Journal publication demonstrates that treatment-emergent cytopenias are consistent with on-target activity, reinforcing physician confidence and supporting durable prescribing patterns. The inclusion of imetelstat in the NCCN chemotherapy order template further reduces administrative barriers, enabling seamless integration into oncology workflows and standardization across treatment centers, which is critical for scaling adoption in community settings where most lower-risk MDS patients are managed.
Geron's financial discipline and operating leverage create a clear path to profitability and cash flow generation in FY26, with Q1 FY26 total operating expenses down 9% year-over-year to $50.4 million despite strategic investments in CMC supply chain strengthening and commercial execution. The company is on track to meet its full-year operating expense guidance of $230 million to $240 million, reflecting sustained cost control from the December 2025 workforce reduction while maintaining investment in high-impact areas like medical affairs and digital promotion. With RYTELO net revenue growing 31% year-over-year to $51.8 million in Q1 FY26 and management guiding to $220–$240 million for the full year—anticipating accelerated growth in the back half due to the lag effect of Q4 FY25 and Q1 FY26 commercial investments—the business model is approaching operating leverage. Gross to net reductions, while increased to 21% in Q1 FY26 due to 340B utilization and GPO contracting, are expected to stabilize in the low to mid-20s for the remainder of the year, indicating manageable pricing pressure as the product matures. This combination of top-line growth and disciplined cost structure positions Geron to achieve non-GAAP profitability before year-end, significantly de-risking the investment thesis and providing internal funding for future opportunities in myelofibrosis or European expansion without dilutive financing.
The ongoing IMpactMF trial in relapsed/refractory myelofibrosis represents a high-conviction, underappreciated catalyst that could substantially redefine Geron's growth trajectory beyond MDS, with interim analysis expected in the second half of FY26. Management emphasized that the trial is fully enrolled and designed to detect overall survival benefit, with confidence bolstered by encouraging survival outcomes in the Phase II EMBARK trial that informed the IMpactMF design. Unlike many myeloid-targeted therapies, imetelstat's mechanism—direct inhibition of telomerase activity—addresses a foundational driver of myelofibrosis pathogenesis, with prior evidence showing reduction in JAK2, CALR, and MPL mutant allele burden, improvement in bone marrow fibrosis, and correlation with clinical benefit. A positive interim result would not only validate imetelstat as a potential first-in-class disease-modifying agent in MF but also create a powerful read-through to RYTELO's value proposition in MDS, reinforcing its disease-modifying narrative and potentially accelerating adoption in both indications. Given the lack of effective disease-modifying options in MF and the high unmet need, a successful interim readout could catalyze partnership interest, accelerate commercial planning, and transform market perception of Geron from a single-product MDS company to a broader hematology innovator with a platform technology, all while leveraging existing commercial and medical affairs infrastructure.

Geron Corporation's RYTELO is positioned to capture significant unmet need in the lower-risk MDS second-line market, with management estimating approximately 8,000 eligible patients in the U.S. and a clear clinical pathway supported by updated NCCN guidelines recommending imetelstat as the preferred second-line treatment. The company's commercial strategy is executing effectively, with first and second-line patient starts increasing to 33% on a rolling 12-month basis in Q1 FY26, up from 30% in the prior quarter, reflecting successful targeted engagement with high-volume community accounts and the 3D surround sound marketing approach. This progression directly addresses a core commercial lever—shifting utilization earlier in the treatment journey—where real-world evidence from the IMerge study and recent Blood Cancer Journal publication demonstrates that treatment-emergent cytopenias are consistent with on-target activity, reinforcing physician confidence and supporting durable prescribing patterns. The inclusion of imetelstat in the NCCN chemotherapy order template further reduces administrative barriers, enabling seamless integration into oncology workflows and standardization across treatment centers, which is critical for scaling adoption in community settings where most lower-risk MDS patients are managed.
Geron's financial discipline and operating leverage create a clear path to profitability and cash flow generation in FY26, with Q1 FY26 total operating expenses down 9% year-over-year to $50.4 million despite strategic investments in CMC supply chain strengthening and commercial execution. The company is on track to meet its full-year operating expense guidance of $230 million to $240 million, reflecting sustained cost control from the December 2025 workforce reduction while maintaining investment in high-impact areas like medical affairs and digital promotion. With RYTELO net revenue growing 31% year-over-year to $51.8 million in Q1 FY26 and management guiding to $220–$240 million for the full year—anticipating accelerated growth in the back half due to the lag effect of Q4 FY25 and Q1 FY26 commercial investments—the business model is approaching operating leverage. Gross to net reductions, while increased to 21% in Q1 FY26 due to 340B utilization and GPO contracting, are expected to stabilize in the low to mid-20s for the remainder of the year, indicating manageable pricing pressure as the product matures. This combination of top-line growth and disciplined cost structure positions Geron to achieve non-GAAP profitability before year-end, significantly de-risking the investment thesis and providing internal funding for future opportunities in myelofibrosis or European expansion without dilutive financing.
The ongoing IMpactMF trial in relapsed/refractory myelofibrosis represents a high-conviction, underappreciated catalyst that could substantially redefine Geron's growth trajectory beyond MDS, with interim analysis expected in the second half of FY26. Management emphasized that the trial is fully enrolled and designed to detect overall survival benefit, with confidence bolstered by encouraging survival outcomes in the Phase II EMBARK trial that informed the IMpactMF design. Unlike many myeloid-targeted therapies, imetelstat's mechanism—direct inhibition of telomerase activity—addresses a foundational driver of myelofibrosis pathogenesis, with prior evidence showing reduction in JAK2, CALR, and MPL mutant allele burden, improvement in bone marrow fibrosis, and correlation with clinical benefit. A positive interim result would not only validate imetelstat as a potential first-in-class disease-modifying agent in MF but also create a powerful read-through to RYTELO's value proposition in MDS, reinforcing its disease-modifying narrative and potentially accelerating adoption in both indications. Given the lack of effective disease-modifying options in MF and the high unmet need, a successful interim readout could catalyze partnership interest, accelerate commercial planning, and transform market perception of Geron from a single-product MDS company to a broader hematology innovator with a platform technology, all while leveraging existing commercial and medical affairs infrastructure.

▼ Bear case

Geron Corporation's reliance on a narrow patient population for RYTELO in lower-risk MDS presents a significant growth ceiling that management has not adequately addressed, with the addressable market of approximately 8,000 second-line patients in the U.S. inherently limiting long-term revenue potential despite current commercial execution. While Q1 FY26 showed progress in shifting utilization to earlier lines (33% of patients on rolling 12-month basis in first/second-line), this metric remains substantially below the 50%+ threshold typically associated with meaningful penetration in early-line settings, and the company provided no clear timeline or strategy for achieving first-line dominance—a critical hurdle given that luspatercept's recent migration to first-line use (cited by management) intensifies competitive pressure and may fragment the second-line opportunity. The NCCN guideline recommendation, while supportive, does not guarantee formulary access or reimbursement parity, and the increasing gross to net reductions (21% in Q1 FY26 vs. 13% in Q1 FY25) signal growing pricing and contracting headwinds from 340B utilization and GPO pressure that could erode net prices as volume scales, directly contradicting management's assumption of stable pricing integrity. Without evidence of expanding into higher-incidence populations (such as higher-risk MDS or comorbid conditions) or demonstrating disease modification in broader MDS subsets, the current commercial trajectory risks plateauing well below the $220–$240 million FY26 guidance range, especially if adoption in the estimated 8,000-patient pool saturates faster than anticipated.
Geron's European commercial strategy remains vague and executionally risky, with management acknowledging pricing as a "very key inflection point" while offering no concrete pathway to market access despite confirming ongoing health technology assessment (HTA) research and expert consultations. The company explicitly ruled out a "classical built-up model" due to resource constraints and expressed only conditional interest in partnerships, yet provided no details on ongoing discussions, timelines for deal execution, or fallback options if preferred structures fail—leaving investors to assume significant near-term opportunity in Europe is speculative. This ambiguity is particularly concerning given that European HTA bodies often impose stricter cost-effectiveness thresholds than U.S. payers, and imetelstat's manufacturing complexity and lack of established real-world outcomes data in the EU could result in pricing significantly below U.S. levels or outright rejection. Furthermore, the expectation to communicate commercial plans "before the end of the year" lacks accountability, as no specific milestones (e.g., HTA submission dates, pricing negotiations, or partnership milestones) were disclosed, increasing the risk of delays that could push meaningful European revenue beyond FY26 and undermine the diversification rationale for the stock's valuation.
The IMpactMF trial's interim analysis in myelofibrosis, while highlighted as a potential upside, carries substantial binary risk that could negatively impact sentiment if results are inconclusive or negative, particularly given the trial's reliance on overall survival as the primary endpoint in a population with high competing mortality risks and heterogeneous disease biology. Management acknowledged that the base case assumes progression to final analysis in the second half of 2028, implying that even a positive interim result would not trigger immediate regulatory action or commercial launch, thereby delaying any meaningful financial contribution until at least FY29. Moreover, the emphasis on JAK2, CALR, and MPL mutation burden reduction as a surrogate for disease modification lacks direct validation in the current trial design, and any failure to demonstrate a clear survival separation—despite mechanistic plausibility—could undermine the core narrative of imetelstat as a first-in-class telomerase inhibitor, raising questions about its translational efficacy across myeloid malignancies. This risk is amplified by the absence of discussion around potential futility stopping rules or biomarker enrichment strategies, suggesting the trial may proceed to full enrollment even if early signals are weak, wasting capital and extending the timeline for clarity on whether imetelstat has broader disease-modifying potential beyond the narrow MDS second-line niche.

Geron Corporation's reliance on a narrow patient population for RYTELO in lower-risk MDS presents a significant growth ceiling that management has not adequately addressed, with the addressable market of approximately 8,000 second-line patients in the U.S. inherently limiting long-term revenue potential despite current commercial execution. While Q1 FY26 showed progress in shifting utilization to earlier lines (33% of patients on rolling 12-month basis in first/second-line), this metric remains substantially below the 50%+ threshold typically associated with meaningful penetration in early-line settings, and the company provided no clear timeline or strategy for achieving first-line dominance—a critical hurdle given that luspatercept's recent migration to first-line use (cited by management) intensifies competitive pressure and may fragment the second-line opportunity. The NCCN guideline recommendation, while supportive, does not guarantee formulary access or reimbursement parity, and the increasing gross to net reductions (21% in Q1 FY26 vs. 13% in Q1 FY25) signal growing pricing and contracting headwinds from 340B utilization and GPO pressure that could erode net prices as volume scales, directly contradicting management's assumption of stable pricing integrity. Without evidence of expanding into higher-incidence populations (such as higher-risk MDS or comorbid conditions) or demonstrating disease modification in broader MDS subsets, the current commercial trajectory risks plateauing well below the $220–$240 million FY26 guidance range, especially if adoption in the estimated 8,000-patient pool saturates faster than anticipated.
Geron's European commercial strategy remains vague and executionally risky, with management acknowledging pricing as a "very key inflection point" while offering no concrete pathway to market access despite confirming ongoing health technology assessment (HTA) research and expert consultations. The company explicitly ruled out a "classical built-up model" due to resource constraints and expressed only conditional interest in partnerships, yet provided no details on ongoing discussions, timelines for deal execution, or fallback options if preferred structures fail—leaving investors to assume significant near-term opportunity in Europe is speculative. This ambiguity is particularly concerning given that European HTA bodies often impose stricter cost-effectiveness thresholds than U.S. payers, and imetelstat's manufacturing complexity and lack of established real-world outcomes data in the EU could result in pricing significantly below U.S. levels or outright rejection. Furthermore, the expectation to communicate commercial plans "before the end of the year" lacks accountability, as no specific milestones (e.g., HTA submission dates, pricing negotiations, or partnership milestones) were disclosed, increasing the risk of delays that could push meaningful European revenue beyond FY26 and undermine the diversification rationale for the stock's valuation.
The IMpactMF trial's interim analysis in myelofibrosis, while highlighted as a potential upside, carries substantial binary risk that could negatively impact sentiment if results are inconclusive or negative, particularly given the trial's reliance on overall survival as the primary endpoint in a population with high competing mortality risks and heterogeneous disease biology. Management acknowledged that the base case assumes progression to final analysis in the second half of 2028, implying that even a positive interim result would not trigger immediate regulatory action or commercial launch, thereby delaying any meaningful financial contribution until at least FY29. Moreover, the emphasis on JAK2, CALR, and MPL mutation burden reduction as a surrogate for disease modification lacks direct validation in the current trial design, and any failure to demonstrate a clear survival separation—despite mechanistic plausibility—could undermine the core narrative of imetelstat as a first-in-class telomerase inhibitor, raising questions about its translational efficacy across myeloid malignancies. This risk is amplified by the absence of discussion around potential futility stopping rules or biomarker enrichment strategies, suggesting the trial may proceed to full enrollment even if early signals are weak, wasting capital and extending the timeline for clarity on whether imetelstat has broader disease-modifying potential beyond the narrow MDS second-line niche.

Segments Breakdown of Revenue (2024)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	206.44 Bn	23.61	5.42	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	179.97 Bn	-62.17	5.91	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	130.57 Bn	29.64	10.37	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	81.63 Bn	18.86	5.25	1.99 Bn
5	ARGX	Argenx Se	primary	60.34 Bn	35.18	11.55	-
6	MRNA	Moderna, Inc.	primary	54.37 Bn	-17.25	24.40	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	33.07 Bn	42.69	6.88	-
8	BIIB	Biogen Inc.	primary	31.84 Bn	38.15	3.17	8.09 Bn

Geron GERN

About

Investment Thesis

Product and Service Breakdown of Revenue (2024)

Segments Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password